Zoetis Inc. (ZTS) SEC Filings

Zoetis Inc. (symbol: ZTS) is the issuer of record for a Form 4 filing submitted to the SEC. SACCARO JAMES reported acquisition or exercise transactions in this Form 4 filing.

Zoetis Inc. (ZTS) reported that EVP, CFO & COO James Saccaro received a compensation-related grant of 81,063 Restricted Stock Units (RSUs) on August 31, 2026. Each RSU represents a contingent right to one share of Zoetis common stock, with one-third scheduled to vest on each of the first, second and third anniversaries of the grant date, subject to continued service and certain earlier-vesting conditions.

Zoetis Inc. (ticker ZTS) disclosed an initial statement of beneficial ownership for executive James Saccaro, who serves as EVP, CFO & COO. The filing reports that he currently has no securities beneficially held in Zoetis, with total direct holdings shown as 0 shares following the reported position.

Zoetis Inc. director Frank A. D'Amelio reported a bona fide gift of 6,650 shares of Zoetis common stock on 2026-08-07. The shares were transferred to the Frank A. D'Amelio 2-Year 2026 GRAT No. 3, where he is grantor, trustee and beneficiary, and are now reported as indirectly held. After the gift, he directly holds 14,808 shares and the trust holds 6,650 shares.

Zoetis Inc. has appointed James (Jay) Saccaro as Executive Vice President, Chief Financial Officer and Chief Operating Officer, effective August 17, 2026. He will serve as the company’s principal financial officer and principal accounting officer, leading global finance and overseeing Global Manufacturing and Supply.

Under an offer letter dated July 31, 2026, Mr. Saccaro will receive a $1,000,000 annual base salary, a target annual bonus equal to 100% of base salary (with his 2026 bonus paid at target and prorated), and an annual long-term incentive opportunity of $5,000,000 in performance stock units, restricted stock units, and stock options. He is eligible for the Executive Severance Plan, relocation assistance, and standard executive benefits. He will also receive a one-time make-whole RSU award of $6,250,000, vesting in three equal annual installments, and a one-time make-whole cash award of $1,250,000 subject to repayment if his employment ends under certain circumstances within his first year.

Current CFO Wetteny Joseph will transition from Executive Vice President and Chief Financial Officer after August 16, 2026 to a non-officer role and will serve as a Special Advisor to the CEO on financial matters until early 2027. Until the earlier of February 28, 2027 or a mutually agreed termination date, he will continue his current salary, benefits, and equity vesting and remain eligible for a 2026 annual incentive award. Upon his termination date, he will receive separation benefits under Section 3.1 of the Executive Severance Plan, with equity treated as upon a “Restructuring Event.” The company states that his departure is not due to any disagreement on operations, policies, practices, accounting, or controls.

Zoetis Inc. reported second-quarter 2026 revenue of $2,468 million, essentially flat versus the prior year and down 1% on an organic operational basis. Net income was $691 million, or $1.65 per diluted share, down 5% and up 1%, respectively, on a reported basis. Adjusted net income was $781 million and adjusted diluted EPS $1.87, down 1% and up 5% on a reported basis and down 2% and up 4% on an organic operational basis.

U.S. revenue fell 7% to $1,266 million, with companion animal sales down 11% amid softer clinic demand, price sensitivity and generic competition, partly offset by 23% growth in U.S. livestock. International revenue rose 8% to $1,173 million, driven by parasiticides, diagnostics and new osteoarthritis monoclonal antibody launches.

Zoetis updated its 2026 outlook, now guiding to revenue of $9.120–$9.320 billion (organic operational revenue growth of (3)% to (1)%), reported net income of $2.330–$2.380 billion, adjusted net income of $2.570–$2.620 billion (organic operational growth of (9)% to (5)%), reported diluted EPS of $5.55–$5.65 and adjusted diluted EPS of $6.15–$6.25, compared with prior adjusted EPS guidance of $6.85–$7.00.

BlackRock, Inc. reports beneficial ownership of Class A stock of Zoetis Inc. on a Schedule 13G/A. As of 06/30/2026, BlackRock and certain reporting business units beneficially owned 37,660,315 Zoetis Class A shares, representing 9.0% of the class.

BlackRock had sole voting power over 34,828,271 shares and sole dispositive power over all 37,660,315 shares, with no shared voting or dispositive power. Various underlying clients and investors have rights to dividends or sale proceeds, but no single person has more than five percent of Zoetis’s outstanding common shares.

Sarbaugh Keith reported acquisition or exercise transactions in this Form 4 filing.

Zoetis Inc. Executive Vice President Keith Sarbaugh received a grant of 259.6384 phantom stock units on July 10, 2026 under the Zoetis Supplemental Savings Plan. These cash-settled units track the value of Zoetis common stock and increase his total phantom stock holdings to 2364.8311 units.

PECK KRISTIN C reported acquisition or exercise transactions in this Form 4 filing.

Zoetis Inc. Chief Executive Officer Kristin C. Peck reported a grant of 616.0892 phantom stock units on 2026-07-10 under the Zoetis Supplemental Savings Plan at $26.2200 per unit. Each unit’s value tracks Zoetis common stock plus cash-equivalent investments and is settled in cash, bringing her balance to 66,194.8959 phantom units.